Click here for slides on this topic


Pravastatin

A drug in the statin (HMG-CoA reductase inhibitor) class that is indicated to treat high cholesterol as an adjunct to diet, and to reduce cardiovascular disease.
The following content matched the glossary term: Pravastatin

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

Risk of incident diabetes among patients treated with statins: population based study

Top

Carter AA, Gomes T, Camacho X, Juurlink DN, Shah BR, Mamdani MM. Risk of incident diabetes among patients treated with statins: population based study. BMJ. 2013;346:f2610 doi:10.1136/bmj.f2610.

Statins and new-onset diabetes: a retrospective longitudinal cohort study

Top

Ma T, Tien L, Fang CL, Liou YS, Jong GP. Statins and new onset diabetes a retrospective longitudinal cohort study. Clin Ther. 2012;34(9):1977-1983. Statins have been linked to new-onset diabetes (NOD); however, the effect of statins on the development of NOD in patients with hypertension and dyslipidemia has not been well studied.

NDEI.org Expert Commentary Statins and Gender Peter Ganz

Top

Expert commentary on statins and gender from Peter Ganz, MD.

Long-term follow-up of the West of Scotland Coronary Prevention Study

Top

Ford I, Murray H, Packard CJ, Shepherd J, Macfarlane PW, Cobbe SM; West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med. 2007;357(15):1477-86. The West of Scotland Coronary Prevention Study was a randomized clinical trial comparing pravastatin with placebo in men with hypercholesterolemia who did not have a history of myocardial infarction, with an average follow-up of approximately 5 years.

Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial

Top

Ahmed S, Cannon CP, Murphy SA, Braunwald E. Acute coronary syndromes and diabetes: Is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J. 2006;27:2323-2329. The impact of intensive lipid lowering therapy with statins in acute coronary syndrome (ACS) patients with diabetes mellitus (DM) is not well characterized.

Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose. Results from the LIPID trial

Top

Keech A, Colquhoun D, Best J, et al. Secondary Prevention of Cardiovascular Events With Long-Term Pravastatin in Patients With Diabetes or Impaired Fasting Glucose. Results from the LIPID trial. Diabetes Care. 2003;26:2713-2721. Diabetes, a major health problem worldwide, increases the risk of cardiovascular disease and its associated mortality. Evidence of the overall benefits of lipid modification in this area is needed.

Does Pravastatin Therapy Prevent the Development of Type 2 Diabetes?

Top

Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001;103(3):357-62. BACKGROUND: We examined the development of new diabetes mellitus in men aged 45 to 64 years during the West of Scotland Coronary Prevention Study.

HMG-CoA Reductase Inhibitors Increase BMD in Type 2 Diabetes Mellitus Patients

Top

Chung Y-S, Lee M-D, Lee S-K, Kim H-M, Fitzpatrick LA. HMG-CoA Reductase Inhibitors Increase BMD in Type 2 Diabetes Mellitus Patients. J Clin Endocrinol Metab. 2000;85:1137-1143. Recently, it was reported that 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors increased bone mineral density (BMD) in mice. We studied the effect of HMG-CoA reductase inhibitors on BMD of type 2 diabetes mellitus by a retrospective review of medical records.



Slide Library Results

Search Results for: Pravastatin Slides Found: 13
ACP Guidelines on Management of Dyslipidemia in Type 2 Diabetes
Results From Statin Trials for Patients With Diabetes
Meta-Analysis: Risk for New-Onset Diabetes and CV Events with Intensive- Vs Moderate Dose Statins
Meta-Analysis: New-Onset Diabetes and CV Events With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: New-Onset Diabetes With Intensive- Vs Moderate-Dose Statins
Meta-Analysis: CV Events With Intensive- Vs Moderate-Dose Statins
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin Over 14 Years
Incident Diabetes Rate Greater with High- Vs Moderate- or Low-Potency Statins
Intensive Statin Therapy and Adverse Events: Meta-Analysis
Incident Diabetes Rate Highest for Atorvastatin, Rosuvastatin Vs Pravastatin for Primary and Secondary Prevention
Incident Diabetes by Statin Use: Design
ACC/AHA Cholesterol Guidelines 2013: High- and Moderate-Intensity Statin Therapy
Statin Adherence & Risk for New-Onset Type 2 Diabetes | NDEI